Skip to main content
Top
Published in: Infection 2/2022

01-04-2022 | Thrombophlebitis | Brief Report

Infected deep vein thrombophlebitis in people who inject drugs: missed opportunities and potential for alternative antimicrobial approaches

Authors: Hugh McCaughan, Clark D. Russell, Dáire T. O’Shea

Published in: Infection | Issue 2/2022

Login to get access

Abstract

Infected deep vein thrombophlebitis (i-DVT) in people who inject drugs (PWID) is a clinically challenging but poorly characterised disease. We undertook a retrospective observational study of 70 PWID presenting acutely with i-DVT to improve the clinical and microbiological characterisation of this disease. i-DVT was frequently associated with bacteraemia (59.1% patients with blood cultures obtained), groin abscesses (in 34.3%; of which 54.2% required surgical drainage), and septic pulmonary emboli (38.6%) requiring anticoagulation. Network analysis identified a cluster of patients presenting with respiratory symptoms but lacking typical DVT symptoms, more likely to have septic pulmonary emboli. A microbiologic diagnosis was frequently achieved (70%). Causative pathogens were predominantly gram-positive (S. aureus and streptococci, especially anginosus group), whereas gram-negative pathogens were identified very infrequently (in 6.1% of microbiological diagnoses). This suggests routine empiric therapy against gram-negative bacteria, though commonly administered, is not required. High rates of clinical cure (88.6%) were observed despite the complex nature of infections and independently of the highly variable intravenous and total antimicrobial durations received. There exists a rationale to devise pragmatic approaches to implement novel individualised treatment plans utilising oral antimicrobial therapy for i-DVT. Despite frequent healthcare interactions, opportunities to address HCV treatment and opioid substitution therapy were frequently missed during these acute admissions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mertz D, Khanlari B, Viktorin N, Battegay M, Fluckiger U. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis. 2008;46(5):741–4.CrossRef Mertz D, Khanlari B, Viktorin N, Battegay M, Fluckiger U. Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users. Clin Infect Dis. 2008;46(5):741–4.CrossRef
2.
go back to reference Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;101(1):68–76.CrossRef Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;101(1):68–76.CrossRef
3.
go back to reference Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open. 2018;1(7):e185220-e.CrossRef Rodger L, Glockler-Lauf SD, Shojaei E, et al. Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs. JAMA Netw Open. 2018;1(7):e185220-e.CrossRef
4.
go back to reference Freeman TC, Horsewell S, Patir A, et al. Graphia: A platform for the graph-based visualisation and analysis of complex data. bioRxiv 2020: 2020.09.02.279349. Freeman TC, Horsewell S, Patir A, et al. Graphia: A platform for the graph-based visualisation and analysis of complex data. bioRxiv 2020: 2020.09.02.279349.
5.
go back to reference Hakeem MBD. Septic deep venous thrombophlebitis and distant emboli in injecting drug users – treatment experience and outcome. J R Coll Phys Edinb. 2007;37(4):293–9. Hakeem MBD. Septic deep venous thrombophlebitis and distant emboli in injecting drug users – treatment experience and outcome. J R Coll Phys Edinb. 2007;37(4):293–9.
6.
go back to reference Fäh F, Zimmerli W, Jordi M, Schoenenberger RA. Septic deep venous thrombosis in intravenous drug users. Swiss Med Wkly. 2002;132(27–28):386–92.PubMed Fäh F, Zimmerli W, Jordi M, Schoenenberger RA. Septic deep venous thrombosis in intravenous drug users. Swiss Med Wkly. 2002;132(27–28):386–92.PubMed
7.
go back to reference Marks LR, Liang SY, Muthulingam D, et al. Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections. Clin Infect Dis. 2020;71(10):e650–6.CrossRef Marks LR, Liang SY, Muthulingam D, et al. Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections. Clin Infect Dis. 2020;71(10):e650–6.CrossRef
8.
go back to reference Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425–36.CrossRef Li HK, Rombach I, Zambellas R, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425–36.CrossRef
9.
go back to reference Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–24.CrossRef Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415–24.CrossRef
10.
go back to reference NHS National Services Scotland, Information Services Division. Drug-Related Hospital Statistics Scotland 2017/18, 2019. NHS National Services Scotland, Information Services Division. Drug-Related Hospital Statistics Scotland 2017/18, 2019.
Metadata
Title
Infected deep vein thrombophlebitis in people who inject drugs: missed opportunities and potential for alternative antimicrobial approaches
Authors
Hugh McCaughan
Clark D. Russell
Dáire T. O’Shea
Publication date
01-04-2022
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-021-01725-3

Other articles of this Issue 2/2022

Infection 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine